IP Library › Granted Patent US 12,054,762
Granted Patent B2
US 12,054,762 · App. 12/107,533 · Granted Aug 6, 2024

Methods of protein production using anti-senescence compounds

Inventors: Jose Manuel Gomes (Chelmsford, MA); Yen-Tung Luan (Chelmsford, MA); Gregory Walter Hiller (Wakefield, MA); Wenge Wang (North Chelmsford, MA)
Assignee: WYETH LLC
C12P21/02C07K14/70578C12P21/005C12N2500/33C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,762
App. No.
12/107,533
Granted
Aug 6, 2024
Kind
B2
Abstract

Methods of producing a protein in cell culture comprising an anti-senescence compound, such as the antioxidant carnosine, are provided. According to teachings of the present invention, cells grown in a cell culture medium comprising an anti-senescence compound exhibit increased viability and productivity. Furthermore, cell cultures grown in the presence of an anti-senescence compound exhibit decreased levels of high molecular weight aggregates in the cell culture medium.

Claims (45)

1. A method of producing a TNFR fusion protein in cell culture comprising steps of:

culturing mammalian cells that contain a gene encoding the TNFR fusion protein, which gene is expressed under conditions of cell culture, in a cell culture medium comprising an anti-senescence compound, wherein the anti-senescence compound is selected from the group consisting of carnosine, acetyl-carnosine, homo-carnosine, anserine, and beta-alanine and combinations thereof; and

maintaining the culture under conditions and for a time sufficient to permit expression of the protein; and

harvesting the cell culture medium, which contains the protein;

and wherein the mammalian cells are Chinese hamster ovary (CHO) cells.

2. The method of claim 1 , wherein the anti-senescence compound comprises carnosine.

3. The method of claim 1 , wherein the anti-senescence compound is present in the cell culture medium at a concentration of between about 5 mM and about 100 mM.

4. The method of claim 1 , wherein the cell culture is further provided with supplementary components.

5. The method of claim 4 , wherein the supplementary components are provided in a feed medium.

6. The method of claim 4 , wherein the supplementary components are selected from the group consisting of hormones, growth factors, sodium, chloride, calcium, magnesium, and phosphate ions, buffers, vitamins, nucleosides or nucleotides, trace elements, amino acids, lipids, glucose, and combinations thereof.

7. The method of claim 5 , wherein the supplementary components include an anti-senescence compound, wherein the anti-senescence compound is selected from the group consisting of carnosine, acetyl-carnosine, homo-carnosine, anserine, and beta-alanine and combinations thereof.

8. A method for producing a TNFR fusion protein comprising steps of:

culturing mammalian cells that contain a gene encoding the TNFR fusion protein in a cell culture medium, which gene is expressed under conditions of cell culture, at a first temperature or temperature range conducive for cell growth during a growth phase;

shifting the temperature or temperature range of the cell culture medium to a second temperature or temperature range conducive for protein production;

culturing the host cells in the cell culture medium at the second temperature or temperature range through a transition phase and into a production phase;

wherein an anti-senescence compound is added to the cell culture, wherein the anti-senescence compound is selected from the group consisting of carnosine, acetyl-carnosine, homo-carnosine, anserine, and beta-alanine and combinations thereof; and

harvesting the cell culture medium, which contains the protein;

wherein the mammalian cells are Chinese hamster ovary (CHO) cells.

9. The method of claim 8 , wherein the anti-senescence compound comprises carnosine.

10. The method of claim 8 , wherein the anti-senescence compound is present in the cell culture medium at a concentration of between about 5 mM and about 100 mM.

11. The method of claim 8 , wherein the cell culture is further provided with supplementary components.

12. The method of claim 11 , wherein the supplementary components are provided in a feed medium.

13. The method of claim 11 , wherein the supplementary components are selected from the group consisting of hormones, growth factors, sodium, chloride, calcium, magnesium, and phosphate ions, buffers, vitamins, nucleosides or nucleotides, trace elements, amino acids, lipids, glucose, and combinations thereof.

14. The method of claim 12 , wherein the supplementary components include an anti-senescence compound selected from the group consisting of carnosine, acetyl-carnosine, homo-carnosine, anserine, and beta-alanine and combinations thereof, wherein the supplementary components include an anti-senescence compound.

15. The method of claim 1 or 8 , wherein the produced TNFR fusion protein is heterologous to the CHO cells.

16. The method of claim 1 or 8 , wherein the TNFR fusion protein comprises TNFR-Fc.

17. The method of claim 16 , wherein the TNFR-Fc is etanercept.

18. A method for preparing a protein according to claim 1 or 8 , further comprising the step of isolating the protein from the cell culture medium.

19. A method according to claim 18 , wherein the protein is further purified or processed for formulation.

20. A method according to claim 19 , wherein the protein is formulated into a pharmaceutical composition.

21. The method according to claim 1 , further wherein the cell culture medium is shifted from a growth phase to a transition phase and a production phase, and wherein the anti-senescence compound is added to the cell culture medium during the transition phase, the production phase, or both the transition phase and production phase.

22. The method according to claim 8 , further wherein the cell culture medium is shifted from a growth phase to a transition phase and a production phase, and wherein the anti-senescence compound is added to the cell culture medium during the transition phase, the production phase, or both the transition phase and production phase.

23. The method according to claim 3 , wherein the anti-senescence compound is present in the cell culture medium at a concentration of about 20 mM.

24. The method according to claim 3 , wherein the anti-senescence compound is present in the cell culture medium at a concentration of about 10 mM to about 40 mM.

25. A method of decreasing accumulation of high molecular weight aggregates during production of a TNFR fusion protein in cell culture comprising steps of:

culturing Chinese hamster ovary (CHO) cells that contain a gene encoding the TNFR fusion protein, which gene is expressed under conditions of cell culture, in a cell culture medium comprising; and

maintaining the culture under conditions and for a time sufficient to permit expression of the protein; and

harvesting the cell culture medium, which contains the protein.

26. The method according to claim 25 , wherein the carnosine is present in the cell culture medium at a concentration of about 10 mM to about 40 mM.

27. The method according to claim 26 , wherein the carnosine is present in the cell culture medium at a concentration of about 20 mM.

28. A method of decreasing accumulation of acidic species during production of a TNFR fusion protein in cell culture comprising steps of:

culturing Chinese hamster ovary (CHO) cells that contain a gene encoding the TNFR fusion protein, which gene is expressed under conditions of cell culture, in a cell culture medium comprising carnosine; and

maintaining the culture under conditions and for a time sufficient to permit expression of the protein.

29. The method according to claim 28 , wherein the carnosine is present in the cell culture medium at a concentration of about 10 mM to about 40 mM.

30. The method according to claim 29 , wherein the carnosine is present in the cell culture medium at a concentration of about 20 mM.

Assignments (2)
CHANGE OF NAME Recorded Jun 16, 2010
From: WYETH
To: WYETH LLC
Reel/Frame 024541/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2008
From: GOMES, JOSE MANUEL; LUAN, YEN-TUNG; HILLER, GREGORY W.; WANG, WENGE
To: WYETH
Reel/Frame 021155/0955 →
Continuity (2)
Provisional Application 60913382 · Apr 23, 2007
Related Publication 20080274507A1 · Nov 6, 2008